Chronic ethanol use in alcoholic beverages by HIV-infected patients affects the therapeutic window of stavudine, lamivudine and nevirapine during the 9-month follow-up period: using chronic alcohol-use biomarkers
Details
The content you want to view is only available to Zendy Plus users.Already have an account? Click here. to sign in.